Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours

2001 ◽  
Vol 33 (7) ◽  
pp. 451-455 ◽  
Author(s):  
Heikki Joensuu ◽  
Sasa Dimitrijevic
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Anticancer Agent ◽  
Kinase Inhibitor ◽  
Solid Tumours

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours

2007 ◽  
Vol 16 (3) ◽  
pp. 367-379 ◽  
Author(s):  
Edwina N Scott ◽  
Gerold Meinhardt ◽  
Christian Jacques ◽  
Dirk Laurent ◽  
Anne L Thomas
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Clinical Development ◽  
Solid Tumours

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

2013 ◽  
Vol 49 (8) ◽  
pp. 1815-1824 ◽  
Author(s):  
Jean-Charles Soria ◽  
José Baselga ◽  
Nasser Hanna ◽  
Scott A. Laurie ◽  
Rastislav Bahleda ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Solid Tumours ◽  
Her 2

scholarly journals Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

2010 ◽  
Vol 103 (7) ◽  
pp. 987-992 ◽  
Author(s):  
I R H M Konings ◽  
M J A de Jonge ◽  
H Burger ◽  
A van der Gaast ◽  
L E C van Beijsterveldt ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Broad Spectrum ◽  
Kinase Inhibitor ◽  
Pharmacological Study ◽  
Solid Tumours
Sign in / Sign up

Export Citation Format

Share Document